In conclusion, these findings underscore the potential of MMP-2 as a biomarker for monitoring PTSD symptom severity, particularly during the early recovery phase (PTSD ≤ 5 years), where it correlates with overall symptom burden and arousal symptoms. The gene discussed is MMP2; the disease is post-traumatic stress disorder.